Antifungal activity of miconazole against recent Candida strains

Mycoses

Volumn 53, Issue 5, 2010, Pages 434-437

  Isham, N ^a   Ghannoum, M A ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Candida; Miconazole; susceptibility

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; CLOTRIMAZOLE; FLUCONAZOLE; ITRACONAZOLE; MICONAZOLE; NYSTATIN; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLINICAL EVALUATION; COMPARATIVE STUDY; FUNGUS ISOLATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, ORAL; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; HUMANS; MICONAZOLE; MICROBIAL SENSITIVITY TESTS;

CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS;

EID: 77955781558     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2009.01728.x     Document Type: Article

References (10)

1. Vazquez JA, Schranz JA, Clark K et al. A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis. J Acquir Immune Defic Syndr 2008 48 : 304 9.
2. Ruhnke M. Epidemiology of Candida albicans infections and role of non-Candida albicans yeasts. Curr Drug Targets 2006 7 : 495 504.
3. Nadagir SD, Chunchanur SK, Halesh LH et al. Significance of isolation and drug susceptibility testing of non-Candida albicans species causing oropharyngeal candidiasis in HIV patients. Southeast Asian J Trop Med Public Health 2008 39 : 492 5.
4. Hamza O, Matee M, Moshi M et al. Species distribution and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasis. BMC Microbiol 2008 8 : 135.
5. Hung CC, Yang YL, Lauderdale TL et al. Colonization of human immunodeficiency virus-infected outpatients in Taiwan with Candida species. J Clin Microbiol 2005 43 : 1600 3.
6. Bassetti M, Righi E, Costa A et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 2006 6 : 21.
7. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard, 2nd edn. CLSI document M27-A2 (ISBN 1-56238-469-4).
8. Vazquez JA. Therapeutic options for the management of oropharyngeal and esophageal candidiasis in HIVAIDS patients. HIV Clin Trials 2000 1 : 47 59.
9. Pienaar ED, Young T, Holmes H. Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children. Cochrane Database Syst Rev 2006 3 : CD003940.
10. Redding SW, Kirkpatrick WR, Dib O et al. The epidemiology of non-albicans Candida in oropharyngeal candidiasis in HIV patients. Spec Care Dentist 2000 20 : 178 81.